Medical device company InspireMD is slated to present the initial results of its 433-patient randomized MASTER trial later this month at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Miami, Fla.
On October 24, Gregg W. Stone, MD, will highlight the company’s MGuard™ embolic protection stent platform technology and its MASTER (MGuard forAcute ST Elevation Reperfusion) study, which demonstrated a positive outcome in patients suffering heart attacks as compared to commercially approved bare metal or drug-eluting stents.
CE Mark-approved MGuard™ Embolic Protection Stent is a coronary stent integrated with a proprietary Micronet technology, which is designed to hold plaque and thrombus in place against the wall of the blocked artery. This wedge prevents debris from falling into the bloodstream, which could cause a potentially fatal downstream blockage.
In eleven previous single arm studies and one 40-patient physician-sponsored randomized trial, the MGuard™ embolic protection stent was effective in restoring blood flow.
“The TCT conference is one of the world’s premier events for new data and developments in interventional cardiology,” Robert Ratini, InspireMD’s vice president of sales and marketing stated in the press release. “We are honored that the committee found the MASTER trial important enough for inclusion in the prestigious Late Breaking Clinical Trials session. We are hopeful this will broaden clinical awareness and adoption of our MGuard Embolic Protection Stent for the benefit of our customer physicians and their patients.”
InspiteMD said that plans for a U.S. FDA registration trial of the MGuard™ embolic protection stent are underway; patient enrollment is expected to begin during the first quarter of 2013.
For more information visit www.inspire-md.com
Let us hear your thoughts below: